Edrecolomab

Names

[ Name ]:
Edrecolomab

Biological Activity

[Description]:

Edrecolomab (Panorex) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, expressed on epithelial tissues and on various carcinomas. Edrecolomab shows anti-tumor activity and can be used in colorectal carcinoma research[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

[In Vitro]

Edrecolomab (0-100 μg/mL; 20 h) shows moderate antibody-dependent cellular cytotoxicity (ADCC)[1]. Cell Cytotoxicity Assay[1] Cell Line: KATO III cells Concentration: 0-100 μg/mL Incubation Time: 20 hours Result: Exhibited an ED50 value>100 ng/ml.

[In Vivo]

Edrecolomab (intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation) treatment inhibits tumor growth in the HT-29 nude mouse model[1]. Animal Model: Male nu/nu mice injected with HT-29 colon carcinoma cells[1] Dosage: 30 μg/dose Administration: Intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation Result: Inhibited tumor growth with a number of significant readings (p≤0.05).

[References]

[1]. Naundorf S, et al. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer. 2002 Jul 1;100(1):101-10.

[2]. Punt CJ, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 2002 Aug 31;360(9334):671-7.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.